A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2018
At a glance
- Drugs Filgotinib (Primary) ; GS 9876 (Primary)
- Indications Lupus nephritis
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 18 Jan 2018 Planned End Date changed from 1 Jan 2021 to 1 Apr 2021.
- 18 Jan 2018 Planned primary completion date changed from 1 May 2020 to 1 Jul 2020.
- 12 Oct 2017 Status changed from not yet recruiting to recruiting.